K. Agrawal, S. Onami, J. Mortimer, and S. Pal, Cognitive changes associated with endocrine therapy for breast cancer, Maturitas, vol.67, issue.3, pp.209-214, 2010.
DOI : 10.1016/j.maturitas.2010.07.004

URL : http://europepmc.org/articles/pmc3253817?pdf=render

J. Baselga, M. Campone, M. Piccart, H. Burris, and H. Rugo, Everolimus in Postmenopausal Hormone-Receptor???Positive Advanced Breast Cancer, New England Journal of Medicine, vol.366, issue.6, pp.520-529, 2012.
DOI : 10.1056/NEJMoa1109653

G. Beatson, On the treatment of inoperable case of carcinoma of the mammary gland :suggestions for a new method of treatment with illustrative cases, Lancet, vol.2, pp.104-111, 1896.

J. Benson, Ovarian ablation as a non-surgical treatment for breast cancer, The Lancet Oncology, vol.9, issue.1, 2008.
DOI : 10.1016/S1470-2045(07)70412-6

S. Bouée, P. Grosclaude, and A. Alfonsi, Projection de l'incidence du cancer du sein en 2018 en France, Bulletin du cancer, vol.97, pp.293-299, 2010.

G. Boutet, Traitement des bouff??es de chaleur apr??s cancer du sein, Gyn??cologie Obst??trique & Fertilit??, vol.40, issue.4, pp.241-254, 2012.
DOI : 10.1016/j.gyobfe.2012.02.015

R. Brock, The life and work of Astley Cooper. Guy's Hospital Report, pp.147-168, 1968.

R. Brueggemeier, J. Hackett, and E. Diaz-cruz, Aromatase Inhibitors in the Treatment of Breast Cancer, Endocrine Reviews, vol.26, issue.3, pp.331-345, 2005.
DOI : 10.1210/er.2004-0015

A. Brufsky, N. Bundred, and R. Coleman, Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole, The Oncologist, vol.13, issue.5, pp.503-514, 2008.
DOI : 10.1634/theoncologist.2007-0206

A. Coates, A. Keshaviah, and B. Thürlimann, Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98, Journal of Clinical Oncology, vol.25, issue.5, pp.486-492, 2007.
DOI : 10.1200/JCO.2006.08.8617

J. Cuzick, I. Sestak, and M. Baum, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, The Lancet Oncology, vol.11, issue.12, pp.1135-1141, 2010.
DOI : 10.1016/S1470-2045(10)70257-6

D. Crivellari, Z. Sun, and A. Coates, Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, issue.12, pp.1972-1979, 2008.
DOI : 10.1200/JCO.2007.14.0459

C. Davies, H. Pan, and J. Godwin, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, The Lancet, vol.381, issue.9869, pp.805-816, 2012.
DOI : 10.1016/S0140-6736(12)61963-1

D. Cremoux and P. , Aromatase, inhibiteurs de l'aromatase et cancers du sein : biologie. La lettre du sénologue, pp.11-14, 2009.

D. Cremoux, P. Debled, M. Bonnefoi, H. Cottu, and P. , Marqueurs biologiques de résistance à l'hormonothérapie dans les cancers du sein, Bulletin du cancer, vol.97, pp.951-963, 2010.

D. Cremoux and P. , Les inhibiteurs de l'aromatase : aspects pharmacologiques, Bulletin du cancer, vol.87, pp.23-30, 2000.

E. Dees and N. Davidson, Ovarian ablation as adjuvant therapy for breast cancer, Seminars in Oncology, vol.28, issue.4, pp.322-331, 2001.
DOI : 10.1016/S0093-7754(01)90126-5

T. Delozier, Hormonoth??rapie du cancer du sein, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.39, issue.8, pp.71-78, 2010.
DOI : 10.1016/j.jgyn.2010.10.004

S. Dent, R. Gaspo, M. Kissner, and K. Pritchard, Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer, Breast Cancer Research and Treatment, vol.17, issue.1, pp.295-310, 2011.
DOI : 10.1093/annonc/mdj127

B. Deroo and K. Korach, Estrogen receptors and human disease, Journal of Clinical Investigation, vol.116, issue.3, pp.561-570, 2006.
DOI : 10.1172/JCI27987DS1

URL : http://europepmc.org/articles/pmc2373424?pdf=render

D. Eilstein, Z. Uhry, and R. Ancelle-park, Estimation de l'impact du dépistage organisé sur la mortalité par cancer du sein, INVS, pp.1-151, 2007.

L. Estévez, I. Alvarez, and I. Tusquets, Finding the right dose of fulvestrant in breast cancer, Cancer Treatment Reviews, vol.39, issue.2, pp.136-141, 2013.
DOI : 10.1016/j.ctrv.2012.06.003

M. Gnant, 10 years of ATAC: one question answered, many others unresolved. The Lancet Oncology, pp.1109-1110, 2010.

P. Goss, J. Ingle, and J. Alés-martínez, Exemestane for Breast-Cancer Prevention in Postmenopausal Women, New England Journal of Medicine, vol.364, issue.25, pp.2381-2391, 2011.
DOI : 10.1056/NEJMoa1103507

J. Guastalla, Hormonothérapie adjuvante de la femme ménopausée. Quels sont les nouveaux standards ? Cancer du sein, pp.385-399, 2006.

J. Hannoun-levi, C. Hennequin, and P. Pommier, Enquête nationale sur la curiethérapie dans le cancer du sein : état des lieux et perspectives en, 2009.

N. Heldring, A. Pike, and S. Andersson, Estrogen Receptors: How Do They Signal and What Are Their Targets, Physiological Reviews, vol.87, issue.3, pp.905-931, 2007.
DOI : 10.1073/pnas.171174298

URL : http://physrev.physiology.org/content/physrev/87/3/905.full.pdf

M. Higgins, CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance, Current Oncology Reports, vol.1, issue.1
DOI : 10.1093/jnci/94.21.1635

J. Yager and N. Davidson, Estrogen Carcinogenesis in Breast Cancer, New England Journal of Medicine, vol.354, issue.3, pp.270-282, 2006.
DOI : 10.1056/NEJMra050776

V. Jenkins, L. Ambroisine, and L. Atkins, Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II), The Lancet Oncology, vol.9, issue.10, pp.953-961, 2008.
DOI : 10.1016/S1470-2045(08)70207-9

Q. Khan, O. Dea, A. Sharma, and P. , Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors, Journal of Oncology, vol.83, issue.2, pp.1-8, 2010.
DOI : 10.1007/s10549-009-0495-x

URL : https://doi.org/10.1155/2010/654348

J. Lester, D. Dodwell, and O. Purohit, Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer, Clinical Cancer Research, vol.14, issue.19, pp.6336-6342, 2008.
DOI : 10.1158/1078-0432.CCR-07-5101

L. Anne, B. Cutuli, and M. Tessier, Place des inhibiteurs de l'aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante : les acquis et les incertitudes en 2005, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.35, pp.327-340, 2006.

L. Anne and R. Maria, Réunion de concertation pluridisciplinaire sous toutes ses formes : présent et avenir, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.41, pp.311-312, 2012.

C. Markopoulos, E. Tzoracoleftherakis, and A. Polychronis, Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial, Breast Cancer Research, vol.34, issue.Suppl 1, pp.12-24, 2010.
DOI : 10.1053/j.seminoncol.2007.10.003

E. Mrózek, R. Layman, B. Ramaswamy, L. Schaaf, X. Li et al., Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer, Clinical Breast Cancer, vol.12, issue.2, pp.151-156, 2012.
DOI : 10.1016/j.clbc.2012.01.003

F. Mccaig, L. Renshaw, and L. Williams, A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer, Breast Cancer Research and Treatment, vol.8, issue.suppl 1, pp.643-641, 2010.
DOI : 10.1093/oxfordjournals.annonc.a010715

URL : https://hal.archives-ouvertes.fr/hal-00535417

S. Nilsson and J. Gustafsson, Estrogen Receptors: Therapies Targeted to Receptor Subtypes, Clinical Pharmacology & Therapeutics, vol.1800, issue.1, pp.44-55, 2011.
DOI : 10.1073/pnas.0905524107

A. Nkondjock and P. Ghadirian, Facteurs de risque du cancer du sein, m??decine/sciences, vol.21, issue.2, pp.175-180, 2005.
DOI : 10.1051/medsci/2005212175

URL : http://www.medecinesciences.org/articles/medsci/pdf/2005/02/medsci2005212p175.pdf

T. Petit and I. Tannock, Faut-il prescrire des inhibiteurs de l'aromatase en phase adjuvante du cancer du sein chez toutes les patientes ménopausées. La lettre du sénologue, pp.16-22, 2009.

P. Pujol, C. Lasset, and P. Berthet, Uptake of a randomized breast cancer prevention trial comparing letrozole to, BRCA1/2 mutations carriers: the LIBER trial

D. Prieto-alhambra, M. Javaid, and S. Servitja, Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study, Breast Cancer Research and Treatment, vol.303, issue.18, pp.869-878, 2011.
DOI : 10.1001/jama.2010.594

URL : https://hal.archives-ouvertes.fr/hal-00561321

H. Rosenbaum, ????Selective estrogen receptor modulators???? (SERM), EMC - Gyn??cologie, vol.3, issue.1, 2008.
DOI : 10.1016/S0246-1064(08)44643-1

R. Sainsbury, Ovarian ablation as a treatment for breast cancer, Surgical Oncology, vol.12, issue.4, pp.241-250, 2003.
DOI : 10.1016/j.suronc.2003.11.002

C. Schilder, C. Seynaeve, and L. Beex, Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial, Journal of Clinical Oncology, vol.28, issue.8, pp.1294-1300, 2010.
DOI : 10.1200/JCO.2008.21.3553

L. Schwartzberg, S. Franco, F. A. O-'rourke, and L. , Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer, The Oncologist, vol.15, issue.2, pp.122-129, 2010.
DOI : 10.1634/theoncologist.2009-0240

V. Shilling, V. Jenkins, and L. Fallowfield, The effects of hormone therapy on cognition in breast cancer, The Journal of Steroid Biochemistry and Molecular Biology, vol.86, issue.3-5, pp.405-412, 2003.
DOI : 10.1016/j.jsbmb.2003.07.001

E. Simpson, M. Mahendroo, and G. Means, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocrine Reviews, vol.15, pp.342-355, 1994.
DOI : 10.1210/er.15.3.342

E. Simpson, C. Clyne, and G. Rubin, Aromatase???A Brief Overview, Annual Review of Physiology, vol.64, issue.1, pp.93-127, 2002.
DOI : 10.1146/annurev.physiol.64.081601.142703

D. Stoppa-lyonnet, M. Stern, N. Soufir, and G. Lenoir, Pr??dispositions g??n??tiques aux cancers??: actualit??s et perspectives en 2010, Pathologie Biologie, vol.58, issue.5, pp.1-7, 2010.
DOI : 10.1016/j.patbio.2010.02.004

URL : http://www.erudit.org/fr/revues/ms/2005-v21-n11-ms1020/011962ar.pdf

A. Tardivon and C. Malhaire, Cancer du sein (I) Epidémiologie, facteurs de risque, imagerie. EMC Radiologie et imagerie médicale-génito-urinaire-gynéco-obstétricale-mammaire, pp.34-800, 2009.
DOI : 10.1016/s1879-8543(09)70668-8

A. Tardivon, C. Malhaire, S. Masson, and . Paris, Cancer du sein (II) Procédures diagnostiques et thérapeutiques Radiologie et imagerie médicale-génito-urinaire-gynéco-obstétricale-mammaire, EMC, vol.34, pp.800-845, 2009.
DOI : 10.1016/s1879-8543(09)70669-x

H. Mouridsen, A. Giobbie-hurder, A. Goldhirsch, B. Thürlimann, R. Paridaens et al., Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, The BIG 1-98 Collaborative Group, pp.766-776, 2009.

F. Trémollières, Effets des inhibiteurs de l'aromatase sur le tissu osseux. Conduite à tenir chez la femme traitée pour cancer du sein. La lettre de sénologie, pp.27-32, 2009.

C. Van-de-velde, D. Rea, and C. Seynaeve, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial, The Lancet, vol.377, issue.9762, pp.321-331, 2011.
DOI : 10.1016/S0140-6736(10)62312-4

D. Barlow, A. Makris, and R. Eastell, Prevention of aromatase inhibitor?induced bone loss using risedronate: The SABRE Trial, Journal of Oncology, vol.28, pp.967-975, 2010.

W. Chie, C. Hsieh, and P. A. Newcomb, Age at Any Full-term Pregnancy and Breast Cancer Risk, American Journal of Epidemiology, vol.151, issue.7, pp.715-722, 2000.
DOI : 10.1093/oxfordjournals.aje.a010266

Z. Dull, B. Neuman, and H. , Management of the axilla. The Surgical clinics of North AmericaWebographie Cancer du sein.org. L'auto exam des seins, pp.429-444, 2013.

. Thériaque, Infos médicaments, 2013.

E. Luporsi, Leichtnam-Dugarin L. Comprendre le cancer du sein. FNCLCC, 2007.

M. Paul, Why women quit breast cancer drugs early Contribution présentée dans le 34 ème symposium du cancer du sein, 2011.